tetano
Editor, Senior Moderator
Expert Opin Investig Drugs
. 2022 Feb 14;1-18.
doi: 10.1080/13543784.2022.2030310. Online ahead of print.
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Enrique Miguez-Rey[SUP] 1 [/SUP], Dasom Choi[SUP] 2 [/SUP], Seungmin Kim[SUP] 2 [/SUP], Sangwook Yoon[SUP] 2 [/SUP], Oana Săndulescu[SUP] 3 [/SUP]
Affiliations
Abstract
Introduction: Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single agents may be effective, but combined treatment involving multiple NAbs may be necessary to prevent the emergence of resistant variants.
Areas covered: This article highlights the accelerated regulatory processes established to facilitate the review and approval of potential therapies. An overview of treatment approaches for SARS-CoV-2 infection, with detailed examination of the preclinical and clinical evidence supporting the use of NAbs, is provided. Finally, insights are offered into the potential benefits and challenges associated with the use of these agents.
Expert opinion: NAbs offer an effective, evidence-based therapeutic intervention during the early stages of SARS-CoV-2 infection when viral replication is the primary factor driving disease progression. As the pandemic progresses, appropriate use of NAbs will be important to minimize the risk of escape variants. Ultimately, the availability of effective treatments for COVID-19 will allow the establishment of treatment algorithms for minimizing the substantial rates of hospitalization, morbidity (including long COVID) and mortality currently associated with the disease.
Keywords: Bamlanivimab and etesevimab; COVID-19; SARS-CoV-2; casirivimab and imdevimab; neutralizing antibodies; regdanvimab; sotrovimab.
. 2022 Feb 14;1-18.
doi: 10.1080/13543784.2022.2030310. Online ahead of print.
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
Enrique Miguez-Rey[SUP] 1 [/SUP], Dasom Choi[SUP] 2 [/SUP], Seungmin Kim[SUP] 2 [/SUP], Sangwook Yoon[SUP] 2 [/SUP], Oana Săndulescu[SUP] 3 [/SUP]
Affiliations
- PMID: 35164631
- DOI: 10.1080/13543784.2022.2030310
Abstract
Introduction: Neutralizing antibodies (NAbs) that target key domains of the spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have therapeutic value because of their specificity. Depending on the targeted epitope, single agents may be effective, but combined treatment involving multiple NAbs may be necessary to prevent the emergence of resistant variants.
Areas covered: This article highlights the accelerated regulatory processes established to facilitate the review and approval of potential therapies. An overview of treatment approaches for SARS-CoV-2 infection, with detailed examination of the preclinical and clinical evidence supporting the use of NAbs, is provided. Finally, insights are offered into the potential benefits and challenges associated with the use of these agents.
Expert opinion: NAbs offer an effective, evidence-based therapeutic intervention during the early stages of SARS-CoV-2 infection when viral replication is the primary factor driving disease progression. As the pandemic progresses, appropriate use of NAbs will be important to minimize the risk of escape variants. Ultimately, the availability of effective treatments for COVID-19 will allow the establishment of treatment algorithms for minimizing the substantial rates of hospitalization, morbidity (including long COVID) and mortality currently associated with the disease.
Keywords: Bamlanivimab and etesevimab; COVID-19; SARS-CoV-2; casirivimab and imdevimab; neutralizing antibodies; regdanvimab; sotrovimab.